Percutaneous Balloon Angioplasty Research Articles

Inferior Vena Cava Rupture Caused by Balloon Angioplasty During the Treatment of Budd-Chiari Syndrome.

Percutaneous transluminal balloon angioplasty (PTA) is the main treatment option for Budd-Chiari syndrome (BCS) with inferior vena cava (IVC) obstruction. However, IVC rupture caused by PTA has never been reported. Between August 2004 and December 2016, a consecutive cohort of 617 BCS patients with obstructed IVC who underwent PTA with or without stent placement were reviewed retrospectively to identify IVC rupture. Pre- and post-procedural imaging data, clinical and procedural technical data were analyzed. Of the 617 BCS patients, five patients had IVC rupture caused by PTA (0.81%). Four of these patients had retroperitoneal, intra-hepatic IVC rupture without extravasation into abdominal cavity which was successfully managed conservatively. One patient had supra-hepatic IVC rupture into the pericardial cavity which was surgically treated. IVC rupture is a rare complication of PTA treatment of BCS and most commonly located at the intra-hepatic IVC caused by oversized balloons which does not require additional treatment.

Low-Dose Paclitaxel-Coated Balloon Angioplasty versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: 6-Month Results in a Tertiary Care Hospital of Central India

Abstract Introduction Superficial femoral and popliteal arteries are the most common locations of peripheral vascular disease (PVD). Endovascular interventional therapy including drug-coated balloon (DEB) angioplasty or percutaneous transluminal angioplasty (PTA) and stenting are important options for treatment of PVD. Aims and Objectives The main objective is to compare the efficacy of DEB over PTA with optional stenting in management of obstructive femoropopliteal lesions in terms of 6-month patency rate. Materials and Methods The clinical experimental study was carried out in a tertiary care center over duration of 2 years. All symptomatic patients having lower limb PVD in femoropopliteal segment were included. Total 37 patients were included in this study in which 16 underwent plain balloon angioplasty (with 3 patients undergoing bare metal stenting [BMS]) and 21 additional underwent DEB angioplasty. Patients with previously intervened lesions, primary lesion failure, major ischemic tissue loss, poor aortoiliac or common femoral inflow, or end-stage kidney disorders were excluded. Result At 1-month follow-up, patency rates in DEB and conventional PTA ± BMS were 85.71% and 87.5%, respectively. On 6-month follow-up, patency rates were found to be 71.4% versus 37.5%, respectively (p = 0.039; significant). In case of occluded lesions, on 6-month follow-up, patency rate in DEB group was higher than that in plain balloon group (66.7% vs. 25%). In both the cohorts, success rate, i.e., patency rates were more in short and intermediate length lesions than long segment lesions. DEB was found to be superior to plain angioplasty with optional stenting in terms of 6-month patency rate.

Results of endovascular interventions in acute lower limb ischemia

The aim — to analyze the results of the use of endovascular revascularization methods for acute lower limb ischemia (ALLI) caused by thromboses or embolisms of the lower limb arteries.Materials and methods. An evaluation of the results of revascularization with the use of endovascular interventions in 108 patients with ALLI was performed. Depending on the treatment method, patients were divided into two groups. The first group included 78 patients who had intra‑arterial catheter‑directed thrombolysis, the second group included 30 patients after percutaneous aspiration or mechanical thrombectomy. If hemodynamically significant residual stenoses of arteries which caused thrombosis remained after thrombolysis or percutaneous thrombectomy, balloon angioplasty or stenting were used.Results and discussion. Technical success was achieved in 73 % of patients who underwent thrombolysis. Endovascular or surgical interventions in addition to thrombolysis were performed in 45 % of patients. The number of perioperative complications was 27 %, of which hemorrhagic — 14 %, including intracranial hemorrhages — 3 %. The number of larger amputations was 21 %, mortality — 8 %. The technical success of aspiration thrombectomy was 83 %, mechanical thrombectomy — 100 %. In most cases additional endovascular interventions were required to eliminate residual stenoses.Conclusions. Endovascular revascularization is an effective method for the treatment of acute lower limb ischemia. Majority of patients after thrombolysis and percutaneous thrombectomy have residual stenotic lesions of arteries which caused thrombosis and require additional endovascular or surgical treatment.

CLINICAL OUTCOMES OF ENDOVASCULAR INTERVENTIONS IN DIABETIC PATIENTS WITH CRITICAL LOWER LIMB ISCHEMIA

The article describes the features of lower limb vessel lesions in patients with diabetes, modern methods for diagnosing critical lower limb ischemia (CLLI), indications for endovascular interventions, and reviews the clinical outcomes of percutaneous transluminal balloon angioplasty in patients with diabetes. The authors emphasized high efficacy of endovascular operations in CLI in patients with diabetes. The issues of the prevention of CLLI and the treatment of the lower limb vascular diseases in diabetes are discussed.

Usefulness of Venous Pressure Measurement in Endovascular Treatment of Budd-Chiari Syndrome: A Retrospective Cohort Study.

Objective Therapeutic predictors derived from the venous pressure before therapy have not been identified for Budd-Chiari syndrome (BCS). The aim of this study was to determine whether or not measuring the distal pressure or pressure gradient was useful for predicting treatment efficacy in BCS. Methods We retrospectively analyzed seven consecutive patients diagnosed with symptomatic BCS at our hospital between 2008 and 2017. Distal and proximal venous pressures at occlusion sites of BCS were measured before treatment in all cases. The pressure gradient was defined as the difference between distal and proximal venous pressures. A receiver operating characteristics (ROC) analysis was performed for venous pressures. Results Percutaneous old balloon angioplasty (POBA) was performed in seven cases, with technical success achieved in all cases (100%). No complications were encountered. The median primary patency was 574 (interquartile range, 439.5-1,056.5) days. The 1-year primary patency rate was 71.73%. Six cases (85.7%) showed resolution of symptoms, representing clinical success. The ROC analysis revealed a high distal pressure (area under the ROC curve = 0.83, cut-off=12 mmHg) as a predictor of treatment efficacy of POBA for symptomatic BCS. In addition, the pressure gradient was considered significant from a clinical perspective, because the 6 successful cases with resolution of symptoms showed a large pressure gradient (range, 8-21 mmHg) before treatment, whereas the failed case showed a relatively small pressure gradient (7 mmHg). Conclusion High distal pressure and a large pressure gradient might predict the treatment efficacy of balloon angioplasty for symptomatic BCS.

Drug-eluting balloon angioplasty versus bare-metal stent in treating chronic total occlusion of femoropopliteal arterial segment: a review of 1-year outcome of 90 patients with TASC C and D lesions

Background Bare-metal stent (BMS) scaffolding of superficial femoral artery occlusive lesions has been associated with high rates of late clinical failure. Maintaining the patency of recanalized arterial segments was the main issue behind the concept of leaving nothing behind to be evolved and percutaneous balloon angioplasty becomes the preferred option for endovascular therapy. Drug-eluting balloons (DEBs) have shown to be an effective alternative to BMS for patients with de novo complex superficial femoral occlusive disease. Aims The aim was to compare the outcome of DEB versus BMS in treating complex chronic total occlusion of superficial femoral and proximal popliteal artery in patients with disabling claudication and critical limb ischemia regarding technical success, primary patency, clinically driven target lesion revascularization (cd-TLR), and limb salvage rate. Materials and methods The current study is a multicenter, prospective, randomized study. Ninety patients (110 limbs) complaining of disabling and critical limb ischemia due to complex femoropopliteal occlusive lesions were randomly allocated into two groups according to the intervention method performed. Group A included 48 patients (57 limbs) who were submitted for treatment with paclitaxel DEBs and group B included 42 patients (53 limbs) submitted for treatment with BMS. The follow-up period was for 1, 6, and 12 months. Statistical analysis was performed by using the IBM SPSS Statistics version 22 for Windows Program Package (SPSS Inc., Chicago, IL, USA). Results BMSs seem to have lower patency and higher cd-TLR rates compared with patients who received paclitaxel drug-coated balloons but was not statistically significant. The primary patency rates were 100, 96, and 86.2% at 1, 6, and 12 months’ respectively’ in the DEB group versus 100, 89.8, and 77.6% at 1, 6, and 12 months, respectively, in the BMS group. Clinically driven TLR rates were 2 and 7.8% at 6 and 12 months, respectively, in the DEB group versus 6.1 and 14.2% at 6 and 12 months, respectively, in the BMS group. Conclusion Percutaneous therapy for Trans atlantic inter-societies consensus (TASC) C and D femoropopliteal lesion using DEB or BMS is safe and effective with a high patency rate of 1 year. Paclitaxel drug-eluting balloons seem to have a promising role in the prevention of restenosis and recurrence of peripheral arterial occlusive disease. However, stents are still playing important bailout role in the treatment of residual stenosis and dissection. Further follow-up is essential to obtain and document long-term outcome of different percutaneous therapy for complex and long superficial femoral artery (SFA) lesions.

BALLOON ANGIOPLASTY OF PERIPHERAL THROMBOSIS IN THE PULMONARY ARTERY AS A PALLIATIVE TREATMENT STRATEGY FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Objective of this study to determine effectiveness and feasibility of percutaneous balloon angioplasty (PBA) of the peripheral pulmonary artery (PA) stenosis in patients with chronic thromboembolic pulmonary hypertension (CTEPH). PBA of 72 PA segments were performed in 50 patients from the ages of

Complicated Evolution of Superior Vena Cava Syndrome Post Cardiac Surgery

Introduction: Superior vena cava syndrome (SVCS) is the clinical manifestation of superior vena cava (SVC) obstruction, with a severe reduction in venous backflow to the right atrium. Symptoms classically include neck, facial and upper limb swelling, development of swollen collateral veins on the front of the chest wall, shortness of breath, coughing, headache, stridor and other neurological complaints, which may all be exacerbated by different postures. CASE REPORT: A 31-year-old man, with a sinus venosus atrial septal defect (SVASD) and partial anomalous pulmonary venous return (PAPVC), was undergone to surgery, in the postoperative course showed a superior vena cava syndrome (SVCS). A second surgery to solve this complication was performed nevertheless, some days after this intervention, the patient developed SVCS symptom’s once again. A new strategy with a large stent implantation in the superior vena cava had acceptable results. The patient kept asymptomatic during four months. Discussion: This syndrome is a rare complication after cardiac surgery; it is associated mostly with bicaval cannulation; various causes such as localized hematoma, swollen absorbable hemostat, and narrowing of the SVC by surgical sutures have been reported. There are no exact guidelines for the clinical management of SVCS. The treatments include long-term anticoagulation, thrombolysis, percutaneous transluminal balloon angioplasty, stent implantation, and open surgical reconstruction. CONCLUSION: This article highlights the importance of bear in mind the potential risk of SVCS during cardiac surgery with bicaval cannulation, whereby the proper precautions must be taken into account. Another outstanding fact of this case report shows the value of working with interventional cardiology department as a team to reach successful results in the benefit of the patients.

Central Venous Stenosis in a Patient on Maintenance Hemodialysis: A Case Report

A 57-year-old male patient of chronic kidney disease on maintenance hemodialysis via right radio-cephalic fistula presented with swelling of his right arm and right half of face and headache. With the clinical suspicion of central venous obstruction he underwent venogram of right upper limb. A stenosis was found in right brachiocephalic vein. He underwent a percutaneous transluminal balloon angioplasty and his symptoms improved substantially.
 Birdem Med J 2019; 9(1): 82-84

Antiplatelet therapy for tibial balloon angioplasty: A clinical perspective.

Percutaneous transluminal tibial balloon angioplasty has an important role in the therapeutic approach of critical limb ischaemia. Despite a growing number of patients with critical limb ischaemia, there are no trials to guide the pharmacologic approach post intervention. Guidelines pertaining to the antiplatelet therapy post percutaneous transluminal tibial balloon angioplasty have not been developed. In addition, critical limb ischaemia patients have multiple comorbidities and a higher risk of bleeding. To examine the shortest duration of antiplatelet therapy post percutaneous transluminal tibial balloon angioplasty, we reviewed the preclinical data used to develop the standards for the current angioplasty technique.

Treatment of Atherosclerotic Disease of the Femoral Artery: Randomized Controlled Trials and Meta-Analyses. Should You Be Sceptical?

A narrative review of the data provided by Randomised Controlled clinical trials and meta-analyses was undertaken to assess how much reliance a clinician could place on these in selecting a treatment for patients with disease of the Femoral artery. An attempt was made to detect and review every clinical trial and meta-analysis published on treatments relating to disease of the femoral artery but not relating to drug treatment. Disease of the femoral artery in >65 years age group occurs in approximately 20% of the population but symptomatology was present in 40%. In almost all trials the predominant (>90%) indication for treatment was intermittent claudication. In this setting, clinical benefit was limited and did not extend beyond 12 months. Mortality, from co-morbidities was high. The Basil Trial was the only one to examine intervention for critical limb ischemia. The results for Bypass surgery and Percutaneous transarterial balloon angioplasty (PTA) were equivalent. There is little evidence to support the use of PTA or stenting other than in the treatment of patients with critical limb ischemia.

VD15 ROSS OPERATION IN AN INFANT

The Ross procedure for replacement of a diseased aortic valve is effective in children where growth capability is essential. Long-term outcomes are generally excellent. Here, we present our technique of choice: the reimplantation of the pulmonary autograft and the implant of a pulmonary Homograft for RVOT replacement in an infant with congebital LVOT stenosis treated with percutaneous balloon angioplasty.

Fistuloplasty using a radiation-and-time-saving sheathless balloon catheter

Introduction:Sheath placement in dialysis access interventions is traditionally necessary to obtain imaging, guide percutaneous angioplasty, and evaluate results. The aim of this study was to assess the feasibility of performing sheathless Arterio-venous (AV) access interventions using a novel percutaneous angioplasty balloon catheter.Methods:Between May and September 2017, data on all dialysis access interventions using a novel percutaneous angioplasty balloon with a dedicated injection port were collected. All procedures were performed without a sheath. Success was established as no conversion to sheath placement. Demographic data, location of lesion, time to perform procedure, amount of contrast used, radiation exposure, and access complications were recorded. Ultrasound was used to evaluate access site complications.Results:Sheathless interventions were successful in 24 patients with the mean age of 62 years (29–94). There were 5 PTFE grafts and 19 native fistulas. Lesions were located anywhere from the arterial anastomosis to the cephalic arch. The average balloon size was 6 mm (5–7 mm), and the procedure time was 15.8 min (8–45 min). No access site complications were observed.Conclusion:Sheathless intervention is feasible with several potential advantages, including short procedure time, minimal contrast volume, and reduced radiation exposure. Finally, the lower profile at the access site may result in fewer complications.

TCT-524 Results of Self-Expanding Nitinol Stents Post-Dilated With Drug-Coated Balloon in Treatment of Femoropoplitial Disease

Bare metal stents (BMS) have better patency results in the femoropopliteal (FP) arterial segments than conventional percutaneous balloon angioplasty (PTA). More recently, drug-coated balloons (DCB) have shown superior outcomes compared to PTA. DCB inhibit neointimal hyperplasia, but unlike BMS,

Acquired Pulmonary Vein Stenosis After Radiofrequency Ablation for Atrial Fibrillation: Single-Center Experience in Catheter Interventional Treatment

ObjectivesThe aim of the present study was to analyze and report a single-center experience with catheter interventional treatment of radiofrequency-induced pulmonary vein stenosis (PVS) following atrial fibrillation (AF) ablation. BackgroundCatheter interventional treatment of radiofrequency-induced PVS following AF ablation remains a challenging field because of a lack of randomized data and treatment guidelines. MethodsAll patients at a single center who underwent catheter interventional treatment for radiofrequency-induced PVS were retrospectively assessed. ResultsFrom January 2004 to September 2017, the total rate of PVS following interventional AF ablation was 0.78% (87 of 11,103). Thirty-nine patients with PVS were treated with 84 catheter interventions: 68 (81%) with percutaneous transluminal balloon angioplasty (PTA) and 16 (19%) with stent implantation. The distribution of stent type was 3 drug-eluting stents (19%) and 13 bare-metal stents (81%). The overall restenosis rate was 53% after PTA versus 19% after stent implantation (p = 0.007) after a median follow-up period of 6 months (interquartile range: 3 to 55 months). The total complication rate for PTA was 10% versus 13% for stenting (p = NS). ConclusionsThis study demonstrates significantly better outcomes in terms of restenosis after stent implantation versus PTA only, with comparable complication rates for these 2 options of interventional treatment of radiofrequency-induced PVS. In summary, despite the lack of randomized studies, the present data and currently available published studies seem to favor stent implantation as a first-line therapy in patients with radiofrequency-induced severe PVS.

Type II Abernethy Malformation in a Patient with Primary Budd-Chiari Syndrome

Budd-Chiari syndrome (BCS) is a heterogeneous group of disorders characterized by hepatic venous outflow obstruction. Abernethy malformation is a congenital vascular malformation defined by diversion of portal blood away from the liver. Both conditions are rare vascular diseases. We report here the first case of a patient with combined type II Abernethy malformation and Budd-Chiari syndrome from China. The inferior vena cava obstruction was treated with percutaneous balloon angioplasty; close follow-up was elected for the Abernethy malformation.

Treatment Strategies for Cephalic Arch Stenosis in Patients with Brachiocephalic Arteriovenous Fistula

Cephalic arch is one of the sites most susceptible to stenosis in brachiocephalic arteriovenous fistula (BCAVF). We performed a retrospective study to identify the incidence of cephalic arch stenosis (CAS) in BCAVF, to compare the patency of percutaneous transluminal balloon angioplasty (PTA) with that of cephalic vein transposition (CVT), and to establish the optimal treatment strategy for CAS. Between January 2011 and June 2016, 462 patients underwent BCAVF creation. CAS was defined as >50% stenosis at the confluence of the cephalic and axillary veins on ultrasonography. Treatment was planned for clinically significant CAS, which was defined as >25% reduction in flow volume compared to previous examination, elevation of venous pressure, delayed puncture site hemostasis, and/or acute thrombotic occlusion. Seventy-seven (16.7%) patients had CAS and 42 of them (54.5%) were treated for clinically significant CAS. PTA was performed in 36 patients (85.7%), and CVT was done in 6 patients (14.3%) as the initial treatment. Nine patients underwent CVT after PTA, resulting in a total of 15 patients treated with CVT. Investigation of the patency of the 36 cases of PTA and 15 cases of CVT revealed that primary-assisted patency rates at 6 and 12months were 68.2% and 57.3% for PTA and 100.0% and 87.5% for CVT, respectively (P=0.038). Secondary patency rates at 6 and 12months were 72.0% and 56.9% for PTA and 100% and 100% for CVT, respectively (P=0.010). The median intervention rate was 2.5 interventions per access-year in the 36 cases treated with PTA and 1.5 interventions per access-year in the 15 cases treated with CVT. CAS is a common cause of BCAVF dysfunction, and careful surveillance is warranted. CVT should be considered for treatment of CAS to achieve better long-term patency with fewer reinterventions.

Utilization of Carbon Dioxide Angiography and Percutaneous Balloon Angioplasty for Treatment of Transplant Renal Artery Stenosis

Utilization of Carbon Dioxide Angiography and Percutaneous Balloon Angioplasty for Treatment of Transplant Renal Artery Stenosis

Endovascular Management for Salvage of Failing Arteriovenous Fistula

Background: Failure of arteriovenous access for hemodialysis is a challenging problem. Maintaining the patency of this access is one of the most important corner stones in the care of patients with chronic renal failure. Recently, percutaneous transluminal balloon angioplasty (PTA) is considered the first line of treatment for dealing with this issue. Aim: The purpose of this retrospective observational study was to evaluate the primary and secondary patency rates after initial endovascular intervention to restore and preserve the patency of failing autogenous arteriovenous fistulae and to identify the potential factors that affect the durability of the procedure. Methods:The results of 56 patients with failing autogenous arteriovenous fistulae were retrospectively analyzed after being treated with percutaneous transluminal balloon angioplasty from November 2014 to December 2018. Technical & clinical success rates were reported. The variables, including patients’ demographics, co-morbidities, medications, fistula age, fistula type, site, number of lesions and degree of stenosis were analyzed and correlated with primary and secondary patency rates. Results: The mean age of the fistulae included in the study since their creation was 17.4 ± 9.6 months, most of which were radiocephalic fistulas (64.3%). The most common cause of autogenous access dysfunction was 90-99% stenosis while the most common site of stenosis was juxta-anastomotic. Technical and clinical success rates of the study population were 92.9% and 89.3%, respectively. The mean primary and secondary patency were 12.3 and 19.9 months, respectively. Primary patency rates at 6,12,18 and 24 months were 79%, 64%, 57% and 44% respectively. Secondary patency rates at 6,12,18 and 24 months were 85%, 76%, 68% and 52% respectively. Patient age ≥ 60 years old was associated with reduced post-PTA primary patency (P < 0.001) and secondary patency (P = 0.018). Dyslipidemia showed marked decrease in both primary and secondary patency rates (P < 0.001). Insulin intake (P < 0.001) was a predictor of primary patency decrease while use of antiplatlets was to a less extent predictor of secondary patency loss (P = 0.004). Radiocephalic fistulae had short primary patency (P = 0.016), while stenotic lesions > 90% showed a significant decrease (P < 0.001) in primary patency more obvious than with secondary patency (P = 0.006). Lesions at arteriovenous anastomosis were significantly associated with decrease in primary patency (P < 0.001). Statins were the only medications associated with longer primary patency (P < 0.001). Age of fistula and number of lesions were independent factors. Conclusion: Endovascular treatment is both safe and effective in managing failing autogenous arteriovenous fistulas. Although its technical and success rates are high, primary and secondary patency rates are still questionable. Dyslipidemia, insulin, statin and antiplatelet intake together with age of patient, degree and site of stenosis are potential risk factors that affect these rates.

Detrimental Effects of Endovascular Intervention in Active Rheumatoid Vasculitis

Balloon angioplasty can cause shear stress and tear of the vascular endothelium during mechanical dilatation, leading to increased inflammation and coagulation reactions of the vascular endothelium. Herein, a worst case of active rheumatoid vasculitis is described, where due to progressing ischemic necrosis of the leg, endovascular intervention was unavoidably performed in the presence of active rheumatoid vasculitis. After percutaneous balloon angioplasty, the patient developed recurrent thrombotic occlusion of the leg arteries, and finally, limb amputation resulted in despite vigorous treatment including medication, immunosuppression, catheter-directed thrombolysis, and post-thrombolysis anticoagulation. This case report indicates that endovascular intervention may be detrimental to the active rheumatoid vasculitis. Until the development of treatment guideline to prevent or control inflammatory reaction, endovascular intervention for the active rheumatoid vasculitis may not be appropriate as a first line therapy even though there is progressing ischemic necrosis.